a 002

Varespladib methyl (LY333013), a bioavailable prodrug of Varespladib, is a selective group II secretory phospholipase A2 inhibitor.

GNA002 is a highly potent, specific, and covalent EZH2 (Enhancer of zeste homolog 2) inhibitor with an IC50 of 1.1 μM.

ATX-002 is a property-tunable lipid for RNA drug delivery.

The S-enantiomer of BET-BAY 002, referred to as BET-BAY 002 S enantiomer, is a potent inhibitor of BET (Bromodomain and Extra-Terminal motif proteins).

BET-BAY 002 is an effective BET bromodomain inhibitor demonstrating efficacy in vivo and in vitro against multiple myeloma and leukaemia models.

BSJ-05-002 serves as a FAK PROTAC.

SPP-002 is a sulfate ester analogue that acts as a potential Sialyltransferase (ST) inhibitor. It selectively inhibits N-glycan sialylation with at least an order of magnitude greater potency compared to the unmodified parent lithocholic acid (LCA). By inhibiting the integrin/FAK/paxillin signaling pathway, SPP-002 reduces tumor cell migration and invasion. It is applicable in research on tumor metastasis.

WZH-17-002 is an ALKPROTAC degrader based on WZH-15-125, with a DC50 of 25 nM. This compound enhances the efficacy against ALK mutations that confer resistance to Lorlatinib. Moreover, WZH-17-002 significantly reduces resistance in ALK fusion non-small cell lung cancer (NSCLC) and inhibits tumor growth in EML4-ALK G1202R/L1196M xenograft mouse models.

I3IN-002 is a small molecule inhibitor targeting the RNA-binding protein IGF2BP3, with an IC50 value of approximately 2 μM in SEM cells. It disrupts the interaction with m6A-modified mRNA, destabilizing target genes (such as CDK6, MYC, and BCL2), thereby inhibiting the growth of leukemia cells, inducing cell cycle arrest, and promoting apoptosis. I3IN-002 shows potential for research in B-cell acute lymphoblastic leukemia.

MolPort-002-705-878 is a highly selective inhibitor of FMS-like tyrosine kinase 3 (FLT3), with a binding affinity of -11.33 kcal/mol. It effectively suppresses the proliferation of FLT3-mutant acute myeloid leukemia (AML) cells and holds potential for research into FLT3-mutant AML.

ABT-002 is a molecular glue degrader that targets GSPT1 and NEK7, and it shows promise for research in hepatocellular carcinoma (HCC).

ZLc-002 is a selective small-molecule inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used in anxiety disorder and inflammation research[1] [2] [3].

OG-L002 is an effective and selective LSD1 inhibitor (IC50: 20 nM), showing 69- and 36-fold selectivity over MAO-A and MAO-B, respectively.

IST5-002 (N6-Benzyladenosine-5'-phosphate) is a selective Stat5a/b inhibitor with anticancer activity that inhibits the transcriptional activity of Stat5a/b and induces apoptosis and death of prostate cancer cells and chronic myelogenous leukemia (CML) cells, which can be used for cancer research.

(Rac)-ZLc-002 is a compound that inhibits the interaction between neuronal nitric oxide synthase (nNOS) and the nitric oxide synthase 1 adaptor protein (NOS1AP), effectively reducing inflammatory pain and chemotherapy-induced neuropathic discomfort. Additionally, it enhances the efficacy of Paclitaxel in decreasing tumor cell viability [1] [2].

ABX-002 (MA-JD21) is a TR-β selective, CNS-penetrant TR-β agonist prodrug, utilized for research on major depressive disorder (MDD) [1].

VLST-002 is a human antibody expressed in CHO cells, targeting CCL5/RANTES. It consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VLST-002 is Human IgG1 kappa, Isotype Control.

L002, a potent, cell-permeable, reversible, and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM, directly binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain. By blocking histone acetylation, p53 acetylation, and STAT3 activation, L002 shows potential in the treatment of hypertension‐induced cardiac hypertrophy and fibrogenesis.

Compound N002-0035 is a useful organic compound for research related to life sciences and the catalog number is T131384.

Compound N002-0028 is a useful organic compound for research related to life sciences and the catalog number is T131385.

Compound N002-0024 is a useful organic compound for research related to life sciences and the catalog number is T131386.

PH-002, an inhibitor targeting the intramolecular domain interaction of apolipoprotein (apo) E4 in neuronal cells, additionally enhances mitochondrial motility and promotes neurite outgrowth, thereby countering related impairments.

DL002 is an ADC linker used to synthesize antibody-drug conjugates that incorporate BCL-2 family protein degraders, intended for cancer research applications.

LN002 is an orally active inhibitor of Cryptosporidium oxidase, utilized for research in cryptosporidiosis.